Inhibrx Biosciences, Inc.
No enriched coverage for $INBX in the last 7 days.
No SEC Form 4 filings for $INBX in the last 30 days.
See all $INBX insider activity →Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.
Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program
Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.
Recent INBX coverage spans financial news, earnings and regulation.
Near-term trading focus is funding runway and regulatory timing for ozekibart, alongside upcoming clinical readouts for INBRX-106 and new Phase 1 cohort interim results.
The Oxford financing and FDA BLA acceptance for ozekibart are near-term risk-reducing catalysts, while the company also reiterated upcoming clinical readouts.
Regulatory acceptance and a fixed PDUFA date reduce timeline uncertainty and can re-rate near-term probability of approval for ozekibart.
The filing signals incremental secured financing capacity and tighter collateralization, which can reduce near-term liquidity risk but may increase leverage and covenant sensitivity.
FDA BLA acceptance is a key regulatory milestone that can re-rate approval odds and extend the timeline for catalysts toward the PDUFA decision.
alphai scores every news story that mentions INBX with an AI model for sentiment and relevance, and aggregates insider trades from Inhibrx Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.
4 min readInhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program
6 min readInhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.
4 min readInhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 oxfordinhibrx-secondamendm.htm EX-10.1 Document Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “ Amendment ”) is entered into as of July 15, 2026, by and among OXFORD FINANCE LLC, a Delaware limite
2 min readInhibrx Biosciences said the U.S. FDA accepted its BLA for Ozekibart to treat unresectable or metastatic conventional chondrosarcoma. The FDA reported no filing review issues and set a PDUFA action date of April 14, 2027. In a Phase 3 trial, Ozekibart cut progression/death risk by 52% vs placebo and increased median PFS to 5.52 months from 2.66.
4 min readInhibrx Biosciences announced positive interim Phase 2 results for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions compared to pembrolizumab alone. The study demonstrated robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 and explore broader indications for OX40 agonism.
4 min readInhibrx Biosciences Inc. ( NASDAQ:INBX ) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90. Check out the current price of INBX stock here. According to Benzinga Pro data, the stock closed regular trading at $28.36, down 10.03%.
2 min readInhibrx Biosciences ( NASDAQ:INBX ) , a clinical-stage biotechnology company specializing in novel biologic therapies, released its second quarter 2025 earnings on August 13, 2025. The most significant news from the release includes a narrower-than-expected GAAP net loss per share and GAAP ...
3 min read
